Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Classical hematology 1

Conditions

Neoplasms 2Waldenstrom Macroglobulinemia 1Solitary Fibrous Tumor, Pleural 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Glioma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Cancer Pain 1Breast Neoplasms 1Anemia 1Anatomic Stage III Breast Cancer AJCC v8 1Adult Patients Who Are Receiving Oncologic Care 1Adjustment Disorders 1

Interventions

venetoclax 69Cyclophosphamide 53ibrutinib 44obinutuzumab 43acalabrutinib 42Rituximab 40fludarabine 37fludarabine phosphate 30Specimen Handling 29pirtobrutinib 25Biopsy 24zanubrutinib 23Whole-Body Irradiation 16Bendamustine Hydrochloride 15Magnetic Resonance Spectroscopy 14Mycophenolic Acid 13Lenalidomide 11Peripheral Blood Stem Cell Transplantation 9Sirolimus 8idelalisib 7Tacrolimus 7CT-P10 7ARQ531 7tafasitamab 6Prednisone 6Busulfan 6pembrolizumab 5Stem Cell Transplantation 5Melphalan 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Pharmacogenomic Testing × 1 year × Clear all
NCT02048813 2026-05-29

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
529 enrolled 12 charts 1 FDA
Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡